At the ESH 11th Translational Research Conference: Myeloproliferative Neoplasms, April 24–26, 2026, Estoril, PT, the MPN Hub held a symposium, titled Patient-centered approaches in myelofibrosis: Tailoring treatment for anemia and thrombocytopenia. During the symposium, MPN Hub Steering Committee member Steffen Koschmieder, Uniklinikum RWTH Aachen, Aachen, DE, delivered a presentation on navigating therapeutic options for patients with cytopenic myelofibrosis.
In this presentation, Koschmieder discusses current therapeutic approaches to cytopenic MF, including a review of key data on outcomes with momelotinib, pacritinib, luspatercept, and pelabresib and selinexor in combination with ruxolitinib.
This educational resource is independently supported by GSK. All content is developed by the faculty in collaboration with SES. Funders are allowed no influence
","author_name":"Scientific Education Support"}